Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$0.20
+0.9%
$0.74
$0.17
▼
$13.54
$2.06M3.155.67 million shs1.87 million shs
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
$0.83
+6.0%
$0.89
$0.68
▼
$2.12
$9.27M0.0113,014 shs5,130 shs
IN8bio, Inc. stock logo
INAB
IN8bio
$0.78
-4.9%
$1.09
$0.72
▼
$2.73
$8.86M0.27293,816 shs30,740 shs
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
$0.72
+0.4%
$0.92
$0.70
▼
$1.88
$8.57M0.9363,680 shs63,429 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-12.85%-32.11%-70.03%-82.18%-97.94%
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
+1.18%-6.33%-11.01%-12.61%-60.45%
IN8bio, Inc. stock logo
INAB
IN8bio
+0.49%-8.89%-26.13%-31.67%-48.43%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-4.65%-11.87%-17.67%-37.63%-45.67%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$0.20
+0.9%
$0.74
$0.17
▼
$13.54
$2.06M3.155.67 million shs1.87 million shs
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
$0.83
+6.0%
$0.89
$0.68
▼
$2.12
$9.27M0.0113,014 shs5,130 shs
IN8bio, Inc. stock logo
INAB
IN8bio
$0.78
-4.9%
$1.09
$0.72
▼
$2.73
$8.86M0.27293,816 shs30,740 shs
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
$0.72
+0.4%
$0.92
$0.70
▼
$1.88
$8.57M0.9363,680 shs63,429 shs
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-12.85%-32.11%-70.03%-82.18%-97.94%
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
+1.18%-6.33%-11.01%-12.61%-60.45%
IN8bio, Inc. stock logo
INAB
IN8bio
+0.49%-8.89%-26.13%-31.67%-48.43%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-4.65%-11.87%-17.67%-37.63%-45.67%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.33
Hold$45.0022,661.76% Upside
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
2.00
Hold$4.16401.20% Upside
IN8bio, Inc. stock logo
INAB
IN8bio
2.00
HoldN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
2.00
Hold$14.001,843.63% Upside

Current Analyst Ratings Breakdown

Latest CODX, GDTC, PHIO, and INAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/11/2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
DowngradeSell (D-) ➝ Sell (E+)
10/27/2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
UpgradeSell (E+) ➝ Sell (D-)
10/15/2026
IN8bio, Inc. stock logo
INAB
IN8bio
Reiterated RatingSell (E+)
10/15/2026
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
Reiterated RatingSell (E+)
10/2/2026
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
Reiterated RatingSell (E+)
9/15/2026
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
Set Price TargetBuy$4.16
9/8/2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
Reiterated RatingSell (E+)
8/26/2026
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
Reiterated RatingBuy
8/18/2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
UpgradeHold ➝ Strong-Buy
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$620K3.35N/AN/A$0.90 per share0.22
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
$250K39.28N/AN/A$0.45 per share1.84
IN8bio, Inc. stock logo
INAB
IN8bio
N/AN/AN/AN/A$1.31 per shareN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/A$0.72 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$46.90M-$6.53N/AN/AN/A-5,530.54%-322.92%-251.11%N/A
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
-$3.10MN/AN/AN/AN/AN/AN/AN/AN/A
IN8bio, Inc. stock logo
INAB
IN8bio
-$19.44M-$1.01N/AN/AN/AN/A-93.66%-78.41%N/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$8.70M-$1.21N/AN/AN/AN/A-101.48%-90.96%N/A

Latest CODX, GDTC, PHIO, and INAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/10/2026Q3 2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$1.25-$1.01+$0.24-$1.01$0.17 million$0.28 million
11/5/2026Q3 2026
IN8bio, Inc. stock logo
INAB
IN8bio
-$0.3367-$0.24+$0.0967-$0.24N/AN/A
11/5/2026Q3 2026
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$0.36-$0.36N/A-$0.36N/AN/A
9/30/2026H1 2026
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
N/A$0.05N/A$0.0490N/A$0.06 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
N/AN/AN/AN/AN/A
IN8bio, Inc. stock logo
INAB
IN8bio
N/AN/AN/AN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
0.77
0.50
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
0.07
2.64
N/A
IN8bio, Inc. stock logo
INAB
IN8bio
N/A
5.78
5.78
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/A
4.19
4.19

Institutional Ownership

CompanyInstitutional Ownership
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
0.04%
IN8bio, Inc. stock logo
INAB
IN8bio
92.05%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
57.31%

Insider Ownership

CompanyInsider Ownership
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
1.70%
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
N/A
IN8bio, Inc. stock logo
INAB
IN8bio
14.50%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
3.52%
CompanyEmployeesShares OutstandingFree FloatOptionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
11510.51 million10.33 millionNo Data
CytoMed Therapeutics Limited stock logo
GDTC
CytoMed Therapeutics
4211.83 millionN/ANot Optionable
IN8bio, Inc. stock logo
INAB
IN8bio
2010.81 million9.24 millionNot Optionable
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
611.95 million11.53 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Co-Diagnostics stock logo

Co-Diagnostics NASDAQ:CODX

$0.20 +0.00 (+0.87%)
Closing price 04:00 PM Eastern
Extended Trading
$0.20 0.00 (-0.35%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

CytoMed Therapeutics stock logo

CytoMed Therapeutics NASDAQ:GDTC

$0.83 +0.05 (+6.00%)
Closing price 03:59 PM Eastern
Extended Trading
$0.82 -0.01 (-1.33%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

IN8bio stock logo

IN8bio NASDAQ:INAB

$0.78 -0.04 (-4.88%)
Closing price 04:00 PM Eastern
Extended Trading
$0.80 +0.02 (+2.18%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. The Company is also developing INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed Glioblastoma (GBM). The preclinical pipeline includes a novel γδ T cell engager platform, INB-600, which activates and expands γδ T cells in vivo for deep target cell depletion and is being developed for oncology and autoimmune indications.

Phio Pharmaceuticals stock logo

Phio Pharmaceuticals NASDAQ:PHIO

$0.72 +0.00 (+0.43%)
Closing price 04:00 PM Eastern
Extended Trading
$0.73 +0.01 (+0.93%)
As of 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.